We are a cancer drug discovery company disrupting the traditional way of treating cancers based upon their tissue of origin – a paradigm that fails most patients.
Our unique approach is rooted in the science of the cancer itself. Changes in the DNA of a cancer cell enable it to grow unchecked, but at the cost of creating weaknesses which can be targeted.
Our next-generation tumour systems, genetic tools and massive datasets, combined with the power of genomics and AI, enable us to identify and exploit cancer’s vulnerabilities.
But not all cancers are the same. Our platforms enable us to select the best targets for drug development with an understanding of which individual patients will respond.
This is the cutting edge of precision healthcare.
We unmask weaknesses in cancer cells that can be targeted to make effective medicines in genetically-defined patient groups.
Using genome-scale CRISPR perturbations in tumour organoid models paired with our industry-validated PRIME computational platform gives us deep knowledge to deliver innovative new therapies.
The PRIME computational platform is an industry- validated proprietary analysis pipeline for cancer drug discovery driven by the power of large-scale genomics and AI.
We use genome-scale CRISPR perturbations to reveal synthetic-lethal tumour cell vulnerabilities and interactions with the immune system using next-generation organoid models.
With a combined expertise of 40 years across cancer genomics, translational research, therapeutics, academia, business leadership, finance, innovation, technology development, commercialisation and protection, MOSAIC’s founding team are highly mission-driven individuals who have dedicated their careers to helping create societal benefit through improved healthcare for every cancer patient.
MOSAIC operates across a variety of biological fields such as synthetic-lethality, DNA damage response, cell death signalling, and immune oncology. We are seeking strategic partnerships that will facilitate rapid uptake of novel targets into drug discovery programmes.
Our capabilities are based on a unique dual technology platform of experimental CRISPR gene-editing in next-generation tumour organoid models and advanced machine-learning and statistical algorithms to selectively identify and exploit the vulnerabilities of different types of cancers. This end-to-end capability gives us a deep knowledge of how to integrate functional and genomic datasets to deliver innovative new therapies.
